Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Alzheimer’s Disease | Unmet Need | Agitation in Alzheimer’s Disease | US/EU | 2022

Login to access report north_east
Contact sales account_box

In addition to cognitive symptoms, the pharmaceutical industry is focusing on treating the neuropsychiatric symptoms of Alzheimer’s disease (AD), including agitation. According to Clarivate epidemiology, agitation affects the majority of patients diagnosed with AD and comprises a constellation of disruptive symptoms for patients and their families. With competing brands from Lundbeck / Otsuka, Axsome Therapeutics, Avanir / Otsuka, and Intra-Cellular Therapies (among others) poised to enter the market beginning in 2023 and with blockbuster sales at stake, understanding the drivers of clinical decision-making in agitation and prescriber perceptions of the risk / benefit profiles of today’s off-label generic options will help identify levers for new product positioning and differentiation in this evolving market.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for agitation in AD?
  • What attributes drive decision-making in agitation in AD, which have limited impact, and which are hidden opportunities?
  • How do current off-label treatments perform on these attributes?
  • Based on a conjoint analysis and TPP simulation, what trade-offs across key clinical attributes and price are neurologists willing to make for a hypothetical new drug to treat agitation in AD?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 32 European neurologists fielded in February 2022

Key companies: Otsuka / Lundbeck, Avanir / Otsuka, Axsome Therapeutics, Intra-Cellular Therapies 

Key drugs: Quetiapine, risperidone, olanzapine, aripiprazole, sertraline, lorazepam, gabapentin, Rexulti, AVP-786, AXS-05, ITI-1284 ODT-SL

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
north_east
Report
Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Macular Edema (US)
Diabetic macular edema (DME) is a serious complication of diabetic retinopathy caused by persistently elevated blood glucose levels. Without timely treatment, DME can progress to significant vision…
north_east
Report
Multiple System Atrophy – Unmet Need – Multiple System Atrophy (US/EU) – Unmet Need – Multiple System Atrophy (US/EU)
Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative synucleinopathy that disrupts movement, balance, and autonomic function. Current management comprises only symptomatic…
north_east
Report
Sarcoidosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Sarcoidosis (US)
Sarcoidosis is a multisystem inflammatory disorder marked by granuloma formation, most often affecting the lungs, lymph nodes, skin, eyes, and heart. Corticosteroids such as prednisone are the…
north_east
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Unmet Need – Unmet Need – Unresectable Locally Advanced or Metastatic Bladder Cancer (US/EU)
The unresectable locally advanced or metastatic bladder cancer treatment landscape continues to evolve, driven by the integration of immunotherapy, targeted agents, and antibody–drug conjugates (…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east